Statin use and risk of dementia or Alzheimer’s disease: a systematic review and meta-analysis of observational studies

Elena Olmastroni1, Giulia Molari2, Noemi De Beni1, Ornella Colpani1, Federica Galimberti1,2, Marta Gazzotti1, Alberto Zambon2,3, Alberico L. Catapano1,2, and Manuela Casula1,2*

1Department of Pharmacological and Biomolecular Sciences, Epidemiology and Preventive Pharmacology Service (SEFAP), University of Milan, Via Balzaretti 9, 20133 Milan, Italy; 2IRCCS MultiMedica, Via Milanese 300, 20099 Sesto S. Giovanni (MI), Italy; and 3Department of Medicine—DIMED, University of Padua, Via Giustiniani 2, 35128 Padua, Italy

Received 2 September 2021; revised 10 November 2021; editorial decision 20 November 2021; accepted 24 November 2021

Aims
As the potential impact of statins on cognitive decline and dementia is still debated, we conducted a meta-analysis of observational studies to examine the effect of statin use on the risk of Alzheimer’s disease (AD) and dementia.

Methods and results
PubMed, Cochrane, and EMBASE were searched since inception to January 2021. Inclusion criteria were: (i) cohort or case–control studies; (ii) statin users compared to non-users; and (iii) AD and/or dementia risk as outcome. Estimates from original studies were pooled using restricted maximum-likelihood random-effect model. Measure of effects were reported as odds ratio (OR) and 95% confidence intervals (CIs). In the pooled analyses, statins were associated with a decreased risk of dementia [36 studies, OR 0.80 (CI 0.75–0.86)] and of AD [21 studies, OR 0.68 (CI 0.56–0.81)]. In the stratified analysis by sex, no difference was observed in the risk reduction of dementia between men [OR 0.86 (CI 0.81–0.92)] and women [OR 0.86 (CI 0.81–0.92)]. Similar risks were observed for lipophilic and hydrophilic statins for both dementia and AD, while high-potency statins showed a 20% reduction of dementia risk compared with a 16% risk reduction associated with low-potency statins, suggesting a greater efficacy of the former, although a borderline statistical significance (P = 0.05) for the heterogeneity between estimates.

Conclusion
These results confirm the absence of a neurocognitive risk associated with statin treatment and suggest a potential favourable role of statins. Randomized clinical trials with an ad hoc design are needed to explore this potential neuroprotective effect.

* Corresponding author. Tel: +39 02 5031 8428, Email: manuela.casula@unimi.it

© The Author(s) 2021. Published by Oxford University Press on behalf of the European Society of Cardiology. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
Introduction

Statins are a class of cholesterol-lowering drugs with proven cardiovascular benefits, validated in different groups of patients. Statins are the cornerstone of pharmacotherapy for atherosclerotic cardiovascular disease, and with the increasing epidemiological burden of hypercholesterolaemia and as newer more stringent lipid goals recommended by latest guidelines, their use is increasingly growing, making statins one of the most commonly prescribed medications worldwide. The role of statins in primary and secondary prevention of cardiovascular disease has been highlighted by the efficacy and safety results reported in a large number of randomized controlled trials and meta-analyses investigating the effects of statins in primary and secondary prevention populations and in subgroups. For each 1 mmol/L reduction in LDL cholesterol, statin reduced the relative risk of major cardiovascular events by 22%, major coronary events by 23%, and coronary artery disease death by 20%. Although cholesterol reduction is the major effect of statins, a number of other, potentially important, effects have been suggested (pleiotropic effects). Among such effects that may be potentially relevant for the onset and clinical progression of dementia and cognitive decline are the anti-inflammatory and antioxidant effects of statins as well as the effect on blood flow and suppression of reactive oxygen species. Statins are generally well-tolerated and have an excellent safety profile but, as with all drugs, adverse reactions may occur in some patients.

Case reports have brought to the attention the reported adverse effect of statin use on cognition, including memory loss, which led in 2012 the US Food and Drug Administration to issue a black box warning for possible adverse effects of statins on cognitive performance. Consumer concerns regarding potential adverse effects of statins are prevalent, so that memory and/or cognitive changes are the second most frequently reported adverse effect during statin therapy. These concerns can compromise acceptance or adherence to statin medications essential to reduce atherosclerotic
cardiovascular risk. With increasing body of evidence, short-term data suggest a lack of adverse effect of statins on cognition, while long-term data seem to support a beneficial role for statins in the prevention of dementia.\cite{14,15} Large-scale trials did not find that statin treatment was associated with dementia or cognitive test scores,\cite{16,17} while in small-scale trials the results have been mixed.\cite{18-20} Also, evidence from observational studies have provided inconsistent results so far,\cite{21-23} with meta-analyses showing variable effects, depending on type of included studies, type of outcome, and characteristics of statins.\cite{22,24,25}

Considered this background, the aim of this study is to provide an updated systematic review and meta-analysis of all observational studies reporting data on the risk of Alzheimer’s disease (AD) and/or dementia, in individuals treated with statins compared with subjects not receiving a lipid-lowering therapy.

**Methods**

This systematic review and meta-analysis has been performed and reported according to the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) and MOOSE (Meta-analyses Of Observational Studies in Epidemiology) guidelines and recommendations.\cite{26,27} Because all the analyses were performed on the basis of previously published studies, no ethical approval or informed consent was required.

**Search strategy**

A systematic and comprehensive literature search was performed on Pubmed, EMBASE databases, and Cochrane Library to retrieve eligible articles from inception to January 2021. Search strategy comprised a combination of terms relevant to the research question, including ‘dementia’, ‘Alzheimer’, and ‘statin’ with Boolean operators as appropriate (see Supplementary material online). The search was restricted to English language and articles available as full text (studies published as abstract were excluded, as well as letters, comments, editorials, case reports).

**Studies selection**

According to PRISMA guidelines, all records retrieved from the search were systematically and sequentially screened, according to titles and abstracts. Each article included after the abstracts screening phase was independently evaluated for full-text eligibility. Any disagreement during each phase was resolved by discussion with a third author.

We included studies which met the following criteria: (i) observational studies (cohort or case–control studies); (ii) adult subjects; (iii) statin users compared to non-users; and (iv) reporting an adjusted estimate [such as odds ratio (OR)/risk ratio (RR)/hazard ratio] and 95% confidence intervals (CIs) for AD and/or dementia risk as outcome. References of included studies were additionally reviewed for other relevant articles, which were not retrieved from the literature search. In case of two or more studies based on the same cohort of subjects and exploring the same outcome(s), only the most recently published was selected and included in the meta-analysis.

**Outcomes definition**

Primary outcomes were AD and dementia defined according to clinical criteria, as the United States National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer’s Disease and Related Disorders Association (NINCDS-ADRDA),\cite{28} the International Classification of Diseases-10/9th edition (ICD-9-CM/ICD-10),\cite{29} the American Psychiatric Association’s Diagnostic and Statistical Manual of Mental Disorders-IV-TR (DSM),\cite{30} or the mini-mental state examination (MMSE) or its modified version (3MSE).\cite{31}

**Data extraction and quality assessment**

Data from the included studies were extracted independently by two authors. Data on sample size, method used for the outcomes definition, estimates of the association of interest, were extracted using a standardized electronic form. Additionally, we collected data about study design and cohort baseline characteristics (i.e. age and sex).

All included studies were also independently evaluated by two authors to assess the risk of several bias. Screening was performed for five main bias categories (selection bias, performance bias, attrition bias, detection bias, and reporting bias). An overall, synthetic grade was produced for each study. The methodological quality of the included studies was evaluated based on the items of modified Newcastle-Ottawa Scale, comprising patient selection, study group comparability and outcome assessment.\cite{32} The observational studies scored 0 to 9. Divergent opinions were discussed among authors and a consensus was reached.

**Statistical analysis**

Outcomes from original studies were pooled and compared using DerSimonian–Laird random-effects method. Measure of effects were reported as OR and 95% CIs. The I-square ($I^2$) test was adopted to evaluate the influence of heterogeneity on the output of the meta-analysis. $I^2$ values of 0%, 25%, 50%, and 75% represented no, low, medium, and high heterogeneity, respectively. Heterogeneity was tested using Cochran Q statistic and the $I^2$ metric.\cite{33} A P-value of <0.05 was accepted as statistically significant. Publication bias was evaluated visually by examining the funnel plot measuring the standard error as a function of effect size, as well as statistically by using the Egger test.\cite{34} We then performed a subanalysis based on patients aged ≥75 years, as well as several stratified analyses according to study design (cohort or case–control studies), sex (men or women), type of statin [predominantly ‘hydrophilic’ statins (rosuvastatin and pravastatin) or predominantly ‘lipophilic’ statins (atorvastatin, simvastatin, lovastatin, and fluvastatin)], and statin potency [‘high potency’ statins (atorvastatin, rosuvastatin, and simvastatin) or ‘low potency’ statins (any other statins)] as defined by included studies. A test of between-group differences based on the Qb statistic is also reported. This test investigates the difference between the group-specific overall effect sizes.

The analyses and the corresponding graphical visualization of forest and funnel plots were conducting using both STATA Version 16 and R Software Program Version 4.0.2.

The data underlying this article are available in the article and in its online supplementary material.

**Results**

**Descriptive study characteristics**

The flow diagram of the literature searches and study selection is shown in Figure 1. Finally, 46 observational studies (38 cohort studies and 8 case–control studies) were included in the meta-analysis. The main characteristics of the studies are summarized in Table 1. All these studies were published between 2000 and January 2021. Samples sizes ranged from 123 to 2 004 692 patients, and 14 out of 46 studies reported a mean participant age ≥75 years old. All studies were of high methodological quality, with only one study reporting a Newcastle-Ottawa scale score of 5 points (Supplementary material online supplementary material).
In total, 25 studies reporting adjusted estimates only for dementia risk, 10 only for AD risk, and 11 studies reporting estimates for both the outcomes.

Meta-analyses results

Overall, 36 observational studies (N 5 738 737) were included in the analysis of dementia risk (Figure 2). We found that statin use was associated with a decreased risk of dementia [OR 0.80 (CI 0.75–0.86)]. Similarly, the analysis of 21 studies (N 1 188 377) showed a significant 32% reduction in the risk of AD among statin users [OR 0.68 (CI 0.56–0.81)] (Figure 3). Visual examination of funnel plots and statistical testing of data from the observational studies for each outcome revealed an apparent publication bias only for dementia risk (Supplementary material online, Figure S2A and B).

The subgroup analysis of patients aged ≥75 years confirmed a statin-associated risk reduction, yielding a 18% reduction in the risk of dementia [OR 0.82 (CI 0.72–0.93)] and 27% reduction in the risk of AD [OR 0.73 (CI 0.54–0.98)] (Supplementary material online, Figure S3A and B).

In subgroup analyses by type of study design (cohort or case–control), no apparent effect modification was found for both the outcomes. Pooled estimates confirmed the risk reduction for dementia, both in cohort studies and in case–control studies [OR 0.81 (CI
### Table 1  Characteristics of observational studies included

| Study                  | Design | Ntotal | Age (minimum as for inclusion criteria; mean) | Sex (% M) | Outcomes | Diagnostic test | Newcastle-Ottawa scale score |
|------------------------|--------|--------|---------------------------------------------|-----------|----------|-----------------|-----------------------------|
| Jick et al. 2000        | CC     | 1364   | >50; NA                                      | 39.5      | D        | NINCDS-ADRDA    | 7                           |
| Rockwood et al. 2002    | CC     | 1315   | >65; 78.05                                   | 38.0      | D, AD    | 3MSE            | 8                           |
| Yaffe et al. 2002       | Co     | 1037   | None; 71.1                                   | 0.0       | D        | 3MSE            | 6                           |
| Zamrini et al. 2004     | CC     | 3397   | None; 73                                     | 100.0     | AD       | ICD-9-CM        | 7                           |
| Li et al. 2004          | Co     | 2356   | >65; 75.1                                    | 40.2      | D        | DSM-IV, NINCDS-ADRDA | 8                  |
| Reitz et al. 2004       | Co     | 1168   | >65; 78.4                                    | 33.3      | AD       | NINCDS-ADRDA    | 7                           |
| Rea et al. 2005         | Co     | 2798   | >65; 75.0                                    | 40.1      | D, AD    | NINCDS-ADRDA    | 6                           |
| Zandi et al. 2005       | Co     | 5092   | >65; 74.6                                    | 45.0      | D, AD    | DSM-III-R, NINCDS-ADRDA, 3MSE | 8                  |
| Green et al. 2006       | CC     | 2378   | None; 67.0                                   | 38.6      | AD       | NINCDS-ADRDA    | 7                           |
| Szwast et al. 2007      | Co     | 1146   | >70; 77.3                                    | 30.7      | D        | DSM-III-R, ICD-10 | 8                  |
| Wolozin et al. 2007     | Co     | 1,290,071 | >65; 74.6                                  | 94.4      | D        | ICD-9           | 6                           |
| Zigman et al. 2007      | Co     | 123    | None; 51.2                                   | 22.8      | AD       | consensus conference | (clinical agreement) |
| Sparks et al. 2008      | Co     | 2068   | >70; 74.7                                    | 45.7      | AD       | DSM-IV, NINCDS-ADRDA | 7                  |
| Arvantakis et al. 2008  | Co     | 929    | >40; 74.9                                    | 31.3      | AD       | MMSE            | 8                           |
| Cramer et al. 2008      | Co     | 1674   | >60; 70.2                                    | 41.7      | D        | DSM-IV, NINCDS-ADRDA, 3MSE | 7                  |
| Smeeth et al. 2009      | Co     | 729,529 | None; NA                                     | 50.3      | AD       | clinical chart record | 8                  |
| Haag et al. 2009        | Co     | 6992   | None; 69.4                                   | 40.0      | AD       | DSM-III-R, NINCDS-ADRDA | 7                  |
| Hippisley-Cox et al. 2010 | Co     | 2,004,692 | >30; 45.8                                  | 49.4      | D        | clinical chart record | 6                  |
| Li et al. 2010          | Co     | 3099   | >65; 75.4                                    | 40.5      | AD       | DSM-IV, NINCDS-ADRDA | 7                  |
| Beydoun et al. 2011     | Co     | 1604   | >50; 57.6                                    | 61.5      | D        | DSM-III-R, NINCDS-ADRDA | 7                  |
| Parkh et al. 2011       | Co     | 377,838 | >65; 75.5                                    | 97.9      | D        | ICD-9-CM        | 6                           |
| Bettermann et al. 2012  | Co     | 3069   | >75; 78.6                                    | 53.8      | D, AD    | DSM-III-R, NINCDS-ADRDA | 7                  |
| Ancelin et al. 2012     | Co     | 6830   | >65; 73.7                                    | 39.7      | D        | DSM-IV, NINCDS-ADRDA | 8                           |
| Douiri et al. 2013      | Co     | 1682   | None; NA                                     | 53.9      | D        | MMSE, AMT       | 7                           |
| Chen et al. 2014        | CC     | 27,716 | >50; 77.5                                    | 48.8      | D        | ICD-9-CM        | 7                           |
| Chen et al. 2014        | Co     | 18,170 | >50; 66.8                                    | 52.3      | D, AD    | ICD-9-CM        | 7                           |
| Chou et al. 2014        | Co     | 103,637| >60; NA                                      | 46.1      | D, AD    | ICD-9-CM        | 8                           |
| Ma et al. 2014          | Co     | 634    | >65; 75.3                                    | 0.0       | AD       | NINCDS-ADRDA    | 8                           |
| Lin et al. 2015         | Co     | 1438   | >50; NA                                      | 30.8      | AD       | ICD-9-CM        | 8                           |
| Chao et al. 2015        | Co     | 256,265| >60; 73.2                                    | 49.7      | D        | ICD-9-CM        | 8                           |
| Chuang et al. 2015      | Co     | 123,300| >20; 54.6                                    | 49.1      | D        | ICD-9-CM        | 8                           |
| Yang et al. 2015        | Co     | 3688   | >65; NA                                      | 33.9      | D        | ICD-9-CM        | 8                           |
| Hendrie et al. 2015     | Co     | 974    | None; 76.6                                   | 30.3      | D, AD    | DSM-IV, ICD-10  | 6                           |
| Chitnis et al. 2015     | Co     | 8062   | None; 74.5                                   | 47.0      | D        | ICD-9-CM        | 8                           |
| Wu et al. 2015          | CC     | 4006   | >65; 72.9                                    | 49.9      | D        | ICD-9-CM        | 8                           |
| Booker et al. 2016      | Co     | 23,912 | >70; 80.4                                    | 39.0      | D        | ICD-10         | 7                           |
| Pan et al. 2018         | Co     | 9448   | >20; 62.5                                    | 55.0      | D        | ICD-9-CM        | 8                           |
| Wandell et al. 2018     | Co     | 12,096 | >45; 72.3                                    | 54.4      | D        | ICD-10         | 7                           |
| Liu et al. 2018         | Co     | 2012   | None; 74.3                                   | NA        | D        | ICD-9-CM        | 8                           |
| Redelmeier et al. 2019  | Co     | 28,815 | >65; 76                                     | 38.7      | D        | ICD-9-CM        | 8                           |
| Chang et al. 2019       | Co     | 100,610| None; 71.7                                   | 46.0      | D        | ICD-9-CM        | 8                           |
| Kim et al. 2020         | Co     | 143,174| >65; 72.2                                    | 40.3      | D        | ICD-10         | 8                           |
| Lee et al. 2020         | Co     | 112,036| >50; NA                                      | 48.4      | D        | ICD-9-CM        | 7                           |
| Lee et al. 2020         | Co     | 6182   | >40; 66.6                                    | 38.6      | D, AD    | ICD-10         | 7                           |
| Torrancell-Haro et al. 2020 | Co     | 288,515 | >45; 66.6                                  | 45.1      | D, AD    | ICD-9-CM        | 9                           |
| Zingel et al. 2020      | CC     | 24,472 | >65; 80.2                                    | 42.3      | D        | ICD-10         | 8                           |
In the stratified analyses by sex, men and women showed the same reduction in the risk of dementia [both OR 0.86 (CI 0.81–0.92), Supplementary material online, Figure S5A]. We observed a non-significant reduction in the risk of AD both for men [OR 0.71 (CI 0.47–1.06)] and women [OR 0.85 (CI 0.48–1.49)], but this evaluation has been limited by the low number of studies reporting this information (Supplementary material online, Figure S5B).

Furthermore, lipophilic and hydrophilic statins induced similar reductions in the risk of dementia [OR 0.83 (CI 0.76–0.90) and OR 0.80 (CI 0.71–0.89), respectively, Supplementary material online, Figure S6] and AD [OR 0.61 (CI 0.46–0.81) and OR 0.59 (CI 0.43–0.74), respectively, Supplementary material online, Figure S6]. Also in this case, the Qb statistic suggested no differences between estimates for both dementia and AD risk (P = 0.61 and P = 0.88, respectively).

Finally, in the stratified analysis by statin potency, high-potency and low-potency statins showed a similar reduction in the risk of dementia [OR 0.80 (CI 0.72–0.88) and OR 0.84 (CI 0.79–0.90), respectively, Supplementary material online, Figure S7]. However, the Qb statistic showed a borderline statistical significance (P = 0.05), suggesting a possible heterogeneity between estimates and leaving open the possibility of a greater efficacy of high-potency statins in reducing the risk of developing dementia.

**Discussion**

Our up to date meta-analysis of 46 observational studies evaluating the association between statin therapy and the incidence of neurocognitive diseases showed that the use of statins not only did not increase the risk of neurocognitive disorders, but rather was associated with a significant risk reduction of 20% of dementia and 32% reduction of AD. This effect was confirmed in the analysis by study design, emphasizing the robustness of this evidence. The benefit was confirmed in both men and women, without any difference in the risk reduction of dementia (-24% in both groups) and with a non-significant risk reduction for AD, probably due to low number of studies reporting the stratified estimates and to heterogeneity among studies.

Our results are in line with a recent meta-analysis including only prospective studies in patients with mean age ≥60 years without cognitive impairment at baseline as well as other previous pooled evaluations with different sets of inclusion criteria.

The majority of the studies included middle-aged adults, a key age-range for an effective cardiovascular disease prevention strategy but also to highlight the potential modulation by statin treatment of cognitive function in the decades ahead. However, our stratified analysis suggests that the beneficial effect of statins is also present in subjects at higher risk of developing dementia due to older age. In the study by Chou et al., the 20% risk reduction observed in the general population ≥60 years was shown to be similar in the subgroup analysis performed according to age (60–69, 70–79, and ≥80 years). Other studies provide evidence of the protective effects of statins also in subjects at higher risk of developing dementia due to predisposing conditions. Chen et al. analysed the incidence of AD among 28,321 patients diagnosed with type 2 diabetes and ≥50 years, showing that a regular statin use was associated with a 13% risk reduction. Zigman et al. reported similar evidence in an analysis of patients with Down syndrome, a condition that increases dramatically the risk of dementia also at relatively younger ages. Moreover, an early statin use was significantly associated with risk reduction in studies evaluating the progression of dementia in subjects with mild cognitive impairment.

We also stratified our meta-analysis based on the type of statins: hydrophilic and lipophilic statins appear to produce similar and significant reductions in the risk of dementia and AD. This is in contrast with previous studies reporting a protective effect limited to lipophilic statins. Interestingly, in the study by Wu et al., the analysis of the effect of different statins showed that higher doses of high-potency statins (atorvastatin and rosuvastatin) had the strongest...
protective effect, suggesting that the potency of statin, rather than drug lipofilicity, was the major factor in reducing dementia. This seems to be confirmed also in our stratified analysis by statin potency, where high-potency statin use was associated with a 20% risk reduction compared with a reduction of 16% of dementia associated with low-potency statins. Our updated meta-analysis included also recent studies, in which the use of rosuvastatin was superior than in the past. Assuming a greater effect for high-potency statins, we might expect the increased use of hydrophilic rosuvastatin in more recent studies to narrow the gap that was observed in previous studies between hydrophilic and lipophilic statins. However, we have also to note that a potential confounding factor in these studies might be represented by the different baseline clinical phenotypes and cardiovascular risk of patients taking high-potency vs. low/medium-potency statins.81

There may be several mechanisms by which statins exert effects on cognition. It has been suggested that some statins may cross the blood–brain barrier and modulate brain cholesterol metabolism, directly altering neurotransmission and synaptic plasticity,86 but this hypothesis is still debated. Statins have also been shown to reduce oxidative stress and inflammation, increase endothelial nitric oxide synthase, and improve endothelial function and blood flow.87 Furthermore, the statin-mediated effect on cognition could be simply
related to their ability in reducing blood cholesterol. However, data from the Hebbinghaus study, where a PCSK9 monoclonal antibody was used, and extremely low LDL cholesterol levels achieved, in the range of 0.8 mmol/L or less, showed no cognitive function deterioration and there were no associations between LDL cholesterol levels and cognitive changes. Further evaluations are needed to clarify this aspect.

A growing body of evidence suggests a close association between lipids and vascular changes in dementia. Hyperlipidaemia, particularly in mid-life, seems to be associated with an increased risk of dementia, potentially by promoting damage to the brain vasculature. Consequently, treating hyperlipidaemia would be expected to reduce the risk of dementia. The hypothesis that statins reduce the risk of dementia by reducing LDL cholesterol levels is supported by the results of studies in which statin use was unrelated to dementia risk for participants with desirable cholesterol levels, but it was associated with a reduced risk in participants with high-cholesterol levels. Moreover, this is in line with evidence from Mendelian randomization studies showing that low LDL-C levels due to 3-hydroxy-3-methylglutaryl-CoA reductase genetic variants did not appear to increase the risk of AD or dementia, as included subjects have lower cholesterol levels since birth, and supports the observation of a greater benefit with high-potency statins. However, this hypothesis is reasonable for dementia with multifactorial etiology and for AD with a relevant ischaemic component, whereas it may not be relevant in ‘pure’ AD forms linked to ApoE genotype and at early onset, which however are rare, particularly among participants in observational studies on statin use.

In the elderly cohort of the Cardiovascular Health Study, Bernick et al. showed that the use of statins was associated with a slight reduction in the rate of cognitive decline during a 7-year period, compared with individuals not taking statins, independently of baseline serum lipid levels. In a subset of participants who underwent two magnetic resonance imaging scans, no differences were observed in white matter or atrophy measures between statin-users and untreated subjects. However, untreated but drug-eligible patients had a greater accumulation of silent subcortically infarcts than the statin-treated group, suggesting the possibility that the accelerated cognitive decline in the statin eligible but untreated participants was due to subclinical vascular disease.

Discordant observations in AD patients might indeed be influenced by the variable degree of concurrent ischaemic cerebrovascular lesions, which may impact the effect of statins on the atherothrombotic contribution to the cognitive decline seen in AD patients. The relative abundance of ischaemic lesional and the predictable impact of aggressive LDL-C-lowering therapy vs. the potential direct effect of statins on amyloid-β or other pathophysiological mechanism(s) of AD might account for the observed different clinical outcomes associated to statin therapy.

The evidence of a neuroprotective effect of statins emerges from observational studies, but not clinical trials. The only long-term randomized trial in the elderly population is the PROSPER (Prospective Study of Pravastatin in Elderly at Risk), which reported comparable cognitive function declines in patients treated with pravastatin or placebo. The Simvastatin Heart Protection Study found no effect on cognitive impairment or dementia after 5 years of follow-up, but the study did not control for dementia risk factors, and dementia ascertainment did not follow the rigorous standards required currently. Moreover, the relatively short follow-up time and a low incidence of dementia may limit drawing conclusions. In the recent Heart Outcomes Prevention Evaluation-3 (HOPE-3) study, which evaluated whether cardiovascular medications can delay cognitive decline, participants were randomized to candesartan plus hydrochlorothiazide or placebo and to rosuvastatin (10 mg) or placebo, using a 2 x 2 factorial design. The primary cognitive outcome measure was change in DSST (Digit Symbol Substitution Test) score. Results showed that candesartan/hydrochlorothiazide, rosuvastatin, and their combination did not reduce or increase the rate of cognitive or functional decline over median follow-up of 5.7 years; the authors suggested that the failure to observe any benefit could be attributed to the relatively short follow-up, the difficulty in retrieving all data and making a correct diagnosis by telephone interviews, and the healthy volunteer bias. A recently published randomized controlled trial on hypertensive patients aged ≥60 years found that rosuvastatin alleviated the progression of cognitive impairment and reduced the risk of dementia over an average of 7-year follow-up.

The ongoing STARER trial, involving healthy individuals aged ≥70 years treated with 40 mg atorvastatin or placebo, with development of dementia among primary outcome measures, has an estimated completion date of 2023.

Our study has several limitations. First, the heterogeneity of diagnostic criteria for dementia, and the use of clinical diagnosis not necessary supported by standardized cognitive test (for example based on ICD codes), as well as different methods to assess the use of statins across included studies may limit the generalizability of the results. This criticism was addressed by Li et al., who evaluated the associations between statin use and the typical AD-related neuropathological outcomes, neurofibrillary tangles, and neuritic plaques using brain autopsy. After controlling for age at death, gender, cognitive score at entry, brain weight, and the presence of microvascular lesions, statin users had a significantly reduced risk for all the outcomes. More in general, this study is a pooled synthesis of observational studies which are susceptible to the effects of bias and confounding by known and unknown factors that are not adequately controlled for, and thus results should be interpreted cautiously, though observational studies can provide data on long-term effects and rarer adverse effects. As an example, the protective effect could be partially explained by the so-called ‘healthy user bias’, which is the propensity for patients who receive one preventive therapy (as statins) to also seek other preventive services or adopt healthy behaviours. The effect of an unmeasured confounder, which might overinflate the observed protective effect was addressed by Corrao et al. In their analysis, a confounder that is three times less frequent among statin users would increase the risk of dementia of five times, or even more, in order to fully explain the observed exposure-outcome association.

Conclusions

The results of this complete and up to date meta-analysis of observational studies:
• suggest that statins are unlikely to cause dementia or cognitive decline, supporting the good safety profile and indications of statin treatment in adult and elderly patients to prevent cardiovascular events;
• support the indication by the recent cardiovascular prevention guidelines strongly recommending the use of statins in secondary prevention in all older subjects and in primary prevention in subjects up to 75 years at high/very high cardiovascular risk to prevent cardiovascular events13;
• highlight that, regarding the possible role of statin therapy for the prevention of dementia, the weakness of pooled data from clinical trials13 and the risk of bias inherent in the observational design, do not allow such a recommendation;
• suggest that indications that aggressive lipoprotein management and statin use as strategy for preventing cognitive decline in elderly persons, requires specifically designed randomized clinical trials, with larger populations, longer follow-up, and standardized and recognized methods for the diagnosis of dementia.

Supplementary material
Supplementary material is available at European Journal of Preventive Cardiology online.

Data availability statement
The data underlying this article are available in the article and in its online supplementary material.1 has been added at the end of Method section.

Funding
The authors received no financial support for the research, authorship, and/or publication of this article. The work of M.C. is supported by Ministry of Health-IRCCS MultiMedica (GR-2016-02361198). The work of A.Z. is supported by Fondazione SISA. The work of A.L.C. is supported by Fondazione Cariplo (2015-0524 and 2015-0564; H2020 REPROGRAM PHC-03-2015/667837-2; ERANET ER-2017-2364981; PRIN 2017H5F943); Ministry of Health-IRCCS MultiMedica (GR-2011-02346974); and SISA Lombardia and Fondazione SISA.

Conflict of interest: All authors declare no support from any organization for the submitted work; no other relationships or activities that could appear to have influenced the submitted work. E.O., G.M., N.D.B., and M.C. report no disclosures. A.L.C. received recognition/fees from Amgen, Eli Lilly, Abbott-Mylan, Sanofi-Regeneron, Amryt, Amarin, and Daiichi Sankyo.

References
1. Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, Chapman MJ, De Backer GG, Delgado V, Ference BA, Graham IM, Halliday A, Landmesser U, Mihaylova B, Pedersen TR, Riccardi G, Richter DJ, Sabatine MS, Taskinen M-R, Tolsgaard L, Wiklund O: ESC Scientific Document Group. 2019 ESC/ESC Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS). Eur Heart J 2020;41:111–188.
2. Smith DG. Epidemiology of dyslipidemia and economic burden on the healthcare system. Am J Manag Care 2007;13:568–571.
3. Pirillo A, Casula M, Olmastroni E, Norata GD, Catapano AL. Global epidemiology of dyslipidemias. Nat Rev Cardiol 2021;18:689–700.
4. Grundy SM, Stone NJ, Bailey AL, Brinton KK, Blumenthal RS, Braun LT, de Ferranti S, Faella-Tommasino J, Forman DE, Goldberg R, Heidenreich PA, Hlatky MA, Jones DW, Lloyd-Jones D, Lopez-Pajares N, Ndumele CE, Orringer CE, Peralta CA, Sassen J, Smith SC Jr, Spering L, Virani SS, Yeboah J. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/AGS/APhA/ASPC/NACC Guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation 2019;139:e1082–e1143.
5. Cholesterol Treatment Trials (CTT) Collaboration, Fulcher J, O’Connell R, Voysey M, Emberson J, Blackwell L, Mihaylova B, Simes J, Collins R, Kirby A, Conroy T, Hantschke H, Braun I, Fowkes FG, M.G., N.D.B., and M.C. report no disclosures. A.L.C. received recognition for the submitted work; no other relationships or activities that could appear to have influenced the submitted work. E.O., G.M., O.C., report no disclosures.

Conflict of interest: All authors declare no support from any organization for the submitted work; no other relationships or activities that could appear to have influenced the submitted work. E.O., G.M., N.D.B., and M.C. report no disclosures. A.L.C. received recognition/fees from Amgen, Eli Lilly, Abbott-Mylan, Sanofi-Regeneron, Amryt, Amarin, and Daiichi Sankyo.

References
1. Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, Chapman MJ, De Backer GG, Delgado V, Ference BA, Graham IM, Halliday A, Landmesser U, Mihaylova B, Pedersen TR, Riccardi G, Richter DJ, Sabatine MS, Taskinen M-R, Tolsgaard L, Wiklund O: ESC Scientific Document Group. 2019 ESC/ESC Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS). Eur Heart J 2020;41:111–188.
2. Smith DG. Epidemiology of dyslipidemia and economic burden on the healthcare system. Am J Manag Care 2007;13:568–571.
3. Pirillo A, Casula M, Olmastroni E, Norata GD, Catapano AL. Global epidemiology of dyslipidemias. Nat Rev Cardiol 2021;18:689–700.
4. Grundy SM, Stone NJ, Bailey AL, Brinter KK, Blumenthal RS, Braun LT, de Ferranti S, Faella-Tommasino J, Forman DE, Goldberg R, Heidenreich PA, Hlatky MA, Jones DW, Lloyd-Jones D, Lopez-Pajares N, Ndumele CE, Orringer CE, Peralta CA, Sassen J, Smith SC Jr, Spering L, Virani SS, Yeboah J. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/AGS/APhA/ASPC/NACC Guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation 2019;139:e1082–e1143.
5. Cholesterol Treatment Trials (CTT) Collaboration, Fulcher J, O’Connell R, Voysey M, Emberson J, Blackwell L, Mihaylova B, Simes J, Collins R, Kirby A, Conroy T, Hantschke H, Braun I, Fowkes FG, M.G., N.D.B., and M.C. report no disclosures. A.L.C. received recognition for the submitted work; no other relationships or activities that could appear to have influenced the submitted work. E.O., G.M., O.C., report no disclosures.

Conflict of interest: All authors declare no support from any organization for the submitted work; no other relationships or activities that could appear to have influenced the submitted work. E.O., G.M., N.D.B., and M.C. report no disclosures. A.L.C. received recognition/fees from Amgen, Eli Lilly, Abbott-Mylan, Sanofi-Regeneron, Amryt, Amarin, and Daiichi Sankyo.
Statin use and risk of dementia: a meta-analysis

69. Carlsson CM, Aparasu RR, Chen H, Kunik ME, Schulz PE, Johnson ML. Use of statins and risk of dementia in heart failure: a retrospective cohort study. Drugs Aging 2019;32:743–754.

70. Wuu C-K, Yang Y-H, Lin T-T, Tsai C-T, Hwang J.J, Lin J-L, Chen P-C, Chiang F-T, Lin L-T. Statin use reduces the risk of dementia in elderly patients: a nationwide data survey and propensity analysis. J Intern Med 2015;277:329–332.

71. Booker A, Jacob LE, Rapp M, Bohiken J, Kostev K. Risk factors for dementia diagnosis in German primary care practices. Int Psychogeriatr 2016;28:1059–1065.

72. Pan ML, Hsu CC, Chen YM, Yu HK, Hsu GC. Statin use and the risk of dementia in patients with stroke: a nationwide population-based cohort study. J Stroke Cerebrovasc Dis 2018;27:3001–3007.

73. Wandell P, Carlson AC, Sundquist J, Sundquist K. Antihypertensive drugs and relevant cardiovascular pharmacotherapies and the risk of incident dementia in patients with atrial fibrillation. Int J Cardiol 2018;272:149–154.

74. Liu JM, Chen TH, Chuang HC, Wu CT, Hsu RJ. Statin reduces the risk of dementia in diabetic patients receiving androgen deprivation therapy for prostate cancer. Prostate Cancer Prostatic Dis 2019;22:276–283.

75. Redelmeier DA, Manzoor F, Thiruchelvam D. Association between statin use and risk of dementia after a concussion. JAMA Neurol 2019;76:887.

76. Chang C-F, Liu Y-S, Lin T-K, Ma S, Hu Y-R, Chen H-Y, Jeng G-P. High exposure to statins decrease the risk of new-onset dementia: a nationwide population-based longitudinal cohort study. Medicine (Baltimore) 2019;98:e16931.

77. Kim M-Y, Jung M, Noh Y, Shin S, Hong CH, Lee S, Jung Y-S. Impact of statin use on dementia incidence in elderly men and women with ischemic heart disease. Biomedicines 2020;8:30.

78. Lee C-Y, Chang C-C, Lin C-S, Yeh C-C, Hu C-J, Wu C-Z, Chen T-L, Liao C-C. Risk of dementia in patients with periodontitis and related protective factors: a nationwide retrospective cohort study. J Clin Periodontol 2020;47:1428–1436.

79. Lee J-W, Choi E-A, Kim Y-S, Kim Y, You H-S, Han Y-E, Kim H-S, Bae Y-J, Kim J, Kang H-T. Statin exposure and the risk of dementia in individuals with hypercholesterolaemia. J Intern Med 2020;288:689–698.

80. Torrondell-Haro G, Brangan GL, Vitali F, Geifman N, Zissimopoulos JM, Brinton RD. Statin therapy and risk of Alzheimer’s and age-related neurodegenerative diseases. Alzheimers Dement 2020;6:e12108.

81. Zingel R, Bohiken J, Riedel-Heller S, Barth S, Kostev K. Association between low-density lipoprotein cholesterol levels, statin use, and dementia in patients followed in German General Practices. J Alzheimers Dis 2021;79:37–46.

82. Ashikara A, Tripathy S, Chuzi S, Peterson J, Stone NJ. Association between statin use and cognitive function: a systematic review of randomized clinical trials and observational studies. J Clin Lipidol 2021;15:22–32.e12.

83. Zhang XY, Wen JZ, Zhang ZQ. Statins use and risk of dementia: a dose-response meta analysis. Medicine 2018;97:e11304.

84. Xu W, Tan L, Wang HF, Jiang T, Tan MS, Tan L, Zhao QF, Li JQ, Wang J, Yu JT. Meta-analysis of modifiable risk factors for Alzheimer’s disease. J Neurol Neurosurg Psychiatry 2015;86:1299–1306.

85. Carlsson CM, Nordahl DM, Klein BEK, McBride PE, Sager MA, Schubert CR, Klein R, Cruickshanks KJ. Increased arteriographic lipoproteins are associated with cognitive impairment: effects of statins and subclinical atherosclerosis. Alzheimers D. Assos Disord 2009;23:11–17.

86. Fracassi A, Marangoni M, Rosso P, Pallottini V, Fioramonti M, Siteni S, Segatto M. Statins and the brain: more than lipid lowering agents? Curr Neuropharmacol 2019;17:59–83.

87. Jain MK, Ridker PM. Anti-inflammatory effects of statins: clinical evidence and basic mechanisms. Nat Rev Drug Discov 2005;4:977–987.

88. Giugliano RP, Mach F, Zavitz K, Kurtz C, Im K, Karvetski E, Schneider J, Wang H, Keetch A, Pedersen TR, Sabatine MS, Sever PS, Robinson JG, Hovanpour N, Wasserman SM, Ott BR. Cognitive function in a randomized trial of evolocumab. N Engl J Med 2017;377:633–643.

89. Williams DM, Finan C, Schmidt AF, Burgess S, Hingorani AD. Lipid lowering and Alzheimer disease risk: a Mendelian randomization study. Ann Neurol 2020;87:30–39.

90. Benn M, Nordestgaard BG, Friis-Kriff Schmidt R, Tybjærg-Hansen A. Low LDL cholesterol, PCSK9 and HMGR genetic variation, and risk of Alzheimer’s disease and Parkinson’s disease: Mendelian randomisation study. BMJ 2017;357:j1648.

91. Bernick C, Katz R, Smith NL, Rapp S, Bhadelia R, Carlson M, Kuller L. Cardiovascular Health Study Collaborative Research Group. Statins and cognitive function in the elderly: the Cardiovascular Health Study. Neurology 2005;65:1388–1394.

92. Kuller LH. Statins, lipids and dementia! J Clin Lipidol 2021;15:18–21.

93. Shepherd J, Blauw GJ, Murphy MB, Bollen ELEM, Buckley BM, Cobb SM, Ford I, Gaw A, Hyland M, Jukema JW, Kamper AM, Macfarlane PW, Meinders AE, Norrie J, Packard CJ, Perry J, Stott D, Sweeney BJ, Twomey C, Westendorp RGJ, PROSPER study group. PROSpective Study of Pravastatin in the Elderly at Risk. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 2002;360:1623–1630.

94. Bosch J, O’Donnell M, Swanmarknathan B, Lonn EM, Sharma M, Dagenais G, Diaz R, Khunti K, Lewis BS, Avexmuz A, Held C, Keltai M, Reid C, Toff WD, Dans A, Leiter LA, Silwa K, Lee SF, Pogue JM, Hart R, Yusuf S. HOPE-3 Investigators. Effects of blood pressure and lipid lowering on cognition: results from the HOPE-3 study. Neurology 2019;92:e1435–e1446.

95. Hu W, Li Y, Zhao Y, Dong Y, Cui Y, Sun S, Gong G, Zhang H, Chai Q, Wang J, Liu Z. Telmisartan and rosvastatin synergistically ameliorate dementia and cognitive impairment in older hypertensive patients with apolipoprotein E genotype. Front Aging Neurosci 2020;12:154.

96. Li G, Larson EB, Sonnen JA, Shrof JB, Petrie EC, Shofer JB, Petrie EC, Schantz A, Peskind ER, Raskind MA, Breitner JCS, Montine TJ. Statin therapy is associated with reduced neuropathologic changes of Alzheimer disease. Neurology 2007;69:878–885.

97. Shrank WH, Patrick AR, Brookhart MA. Healthy user and related biases in observational studies of preventive interventions: a primer for physicians. J Gen Intern Med 2011;26:546–550.

98. Corrao G, Ibrahim B, Nicostra F, Zambon A, Merlino L, Pasini TS, Catapano AL, Mancia G. Long-term use of statins reduces the risk of hospitalization for dementia. Alzheimers Dementia 2013;230:171–176.

99. Cholesterol Treatment Trialists’ Collaboration. Efficacy and safety of statin therapy in the primary prevention of cardiovascular disease: a meta-analysis of individual participant data from 90% of randomized trials including 1·9 million participants. Lancet 2015;386:37–72.

100. Moher D, Liberati A, Tetzlaff J, Altman DG; The PRISMA Group. Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement. PLoS Med 2009;6:e1000097.